In this issue:
Interim trial analysis of glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP for DLBCL
High rates of end-consolidation MRD negativity in the SUBLIME study
Predicting treatment outcome in multiple myeloma
Outcomes of post allogeneic stem cell transplantation in CLL
Sensitive measurement of MRD in relapsed CML patients stopping therapy
Real-world outcomes of patients with DHL in the Royal Melbourne Hospital
Long-term efficacy and safety of zanubrutinib in patients with MZL
Incidence, prevalence, and mortality of WM in Australia
Use of haploidentical donor stem cells increases the risk of CMV for GVHD prophylaxis
Intensive pegcetacoplan dosing for acute haemolysis
Please login below to download this issue (PDF)